About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Unicystic Ameloblastoma with Mural Proliferation
Ilknur Eninanç1, Defne Yalçin Yeler1, Halit Sengel2, Hasan Yeler2, Ömer Fahrettin Göze3
Departments of 1Oral and Maxillofacial Radiology and 2Oral and Maxillofacial Surgery, Faculty of  Dentistry; 3Department of Pathology, Medical Faculty, Sivas Cumhuriyet University, Sivas, Turkey.
Corresponding Author:
Dr Ilknur Eninanç
Email: i.eninanc2@gmail.com
Received: 10-JAN-2021 Accepted: 19-MAR-2021 Published Online: 30-MAY-2021
DOI: http://dx.doi.org/10.17659/01.2021.0030
Abstract
Background: Unicystic ameloblastoma (UA) is a rare variant of ameloblastoma and represents about 6% of all ameloblastomas. Radiologically, it is very similar to odontogenic jaw cysts due to its unilocular radiolucency. Case Report: This report discusses the clinical, radiological, histopathological and surgical findings of mural unicystic ameloblastoma occupying the right maxillary sinus on a background of dentigerous cyst associated with an impacted tooth in a 22-year-old female patient. Conclusion: It is very uncommon to see this lesion in the maxilla since it usually involves the posterior region of the mandible. Differentiation of an UA from a dentigerous cyst is radiographically difficult when UA is associated with an impacted tooth. Among all UA types, UA with mural proliferation has the highest rate of recurrence. Long-term follow-up for recurrence should be considered for patients with UA.  
Keywords : Ameloblastoma, Dentigerous Cyst, Mandible, Maxilla, Odontogenic Cysts.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Jan 02, 2025